An immune pathway best known for spotting stray DNA inside cells is drawing fresh attention as a driver of inflammation in the brain. A review published in the Journal of Clinical Investigation gathers the evidence on cyclic GMP-AMP synthase (cGAS) and its partner protein, stimulator of interferon genes (STING), and their expanding role in neuroinflammation, brain aging, and neurodegenerative disease.
The biology is straightforward in outline. Cells carry pattern recognition receptors that act as sentinels for nucleic acids, whether they come from an invading pathogen or from the cell's own damaged genome. cGAS is one of these sensors: it binds double-stranded DNA in the nucleus and cytosol regardless of the sequence, then switches on STING, which triggers a powerful type I interferon response. That reaction is useful against infection, but when it fires persistently in the brain it becomes a problem.
Neuroinflammation is a hallmark of Parkinson's disease, Alzheimer's disease, and Huntington's disease, and the review authors point to dysregulated cGAS-STING signaling as a contributor to both brain aging and neurodegeneration. The same pathway also figures in anti-tumor immunity and tumor formation, which is part of why it has been so heavily studied and why a body of pharmacology already exists around it.
The practical interest here lies in targets. If chronic interferon signaling through cGAS-STING helps sustain the inflammatory state seen in these diseases, the pathway offers a defined point of intervention rather than a vague call to reduce inflammation. This is a review of existing work rather than a new experiment, so it maps the terrain and the therapeutic potential others will need to test.